News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advanced Bio-Surfaces, Inc. Announces Initial Experiences Of OrthoGlide(TM) Medial Knee Implant


5/25/2006 2:46:41 PM

MINNEAPOLIS, May 25 /PRNewswire/ -- Advanced Bio-Surfaces, Inc. (ABS), an orthopedic implant developer and manufacturer, announced today the completion of ten OrthoGlide Medial Knee implants in the USA.

"We're excited to report ten patients have received the OrthoGlide implant at sites in the USA," said Dr. Jeff Felt, Chairman and CEO of Advanced Bio- Surfaces. "The availability of the OrthoGlide implant is important to people suffering from osteoarthritis of the knee. Prior to OrthoGlide's clearance to market, patients would have undergone a total knee replacement or other invasive procedure."

One of the first orthopedic surgeons to implant the OrthoGlide Medial Knee Implant in the USA is David Raab, M.D. at Illinois Bone and Joint Institute in Chicago, Illinois. Dr. Raab stated, "Early results show patients are doing well with good pain relief, minimal swelling and near full range of motion." Dr. Raab continued, "Two of my patients have osteoarthritis in their contralateral knee and have already inquired about having the other knee done as well."

Michael Purnell, M.D. practicing at OrthoMed Center in Modesto, California has also completed OrthoGlide implants and shared his thoughts on the implant procedure, "From a surgical standpoint the OrthoGlide is easy to implant, especially when compared to a total knee replacement. In addition, the OrthoGlide required only a small incision and no bone cuts. The OrthoGlide implant procedure, in my opinion, has a positive effect on a patient's chance for a faster recovery time and short length of stay in the hospital. The patients I have implanted have a high level of satisfaction with their initial pain relief."

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint repair products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) and CE mark notification from its Notified Body, TUV Product Services (Munich) in February of this year. For additional information contact Robert Siegfried at 952.912.5400.

Advanced Bio-Surfaces, Inc.

CONTACT: Robert Siegfried VP, Finance and Administration, Advanced Bio-Surfaces, Inc., +1-952-912-5400


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES